PT Indofarma Tbk (INAF.JK) Stock
PT Indofarma Tbk

Company profile
PT Indofarma Tbk reported revenue of 210.38 billion IDR for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was 66.71 billion IDR. Indonesia was its largest region in fiscal year 2024, with 93% of revenue. In Q3 2025 it reported a net loss of 83.54 billion IDR, against a net loss of 64.54 billion IDR a year earlier. Our analysis of its filings shows revenue shrinking from 980.37 billion IDR in fiscal year 2022 to 210.38 billion IDR in fiscal year 2024, 53.7% a year on average. PT Indofarma Tbk reports about 39 full-time employees.
What stands out
- Revenue fell 59.8% in fiscal year 2024, from 523.60 billion IDR in fiscal year 2023, after a fall of 46.6% the year before.
- It reported a net loss in each of its last 4 fiscal years, after a profit of 27.58 million IDR in fiscal year 2020; the loss narrowed from 720.99 billion IDR in fiscal year 2023 to 334.49 billion IDR in fiscal year 2024.
- Revenue turned up in Q3 2025: up 137.0% from a year before.
- Medicine brought in 50% of segment revenue in fiscal year 2024, down from 65% in fiscal year 2023.
Figures from company filings; latest fiscal year ended December 31, 2024.
About PT Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company operates through medicine, Medical devices and Others, and Engineering Pharmaceuticals. It engages in marketing, trading and distribution of medicine and medical devices; and clinical lab. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is based in Bekasi, Indonesia. The company operates as a subsidiary of PT Bio Farma.
Leadership
- Sahat Sihombing — President Director, 59
- Andi Prazos Apt, M.M. — Director of Operations & Director, 56
- Warjoko Sumedi — Head of Internal Audit Unit, 54
- Hilda Yani — Company Secretary, 49
- Weny Maulatsih — Secretary of Board of Commissioners, 40
How much revenue does PT Indofarma Tbk make?
PT Indofarma Tbk reported 210.38 billion IDR in revenue for fiscal year 2024, down 59.8% from 523.60 billion IDR in fiscal year 2023. In Q3 2025 revenue was 66.71 billion IDR.
What is PT Indofarma Tbk's largest business segment?
Medicine, with 106.16 billion IDR or 50% of segment revenue in fiscal year 2024. Next: Medical Devices & Others (50%).
Where does PT Indofarma Tbk make most of its revenue?
Indonesia: 93% of revenue by region in fiscal year 2024, followed by Export (7%).
What companies are similar to PT Indofarma Tbk?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Darya-Varia Laboratoria Tbk (DVLA.JK), PT Pyridam Farma Tbk (PYFA.JK), PT Merck Tbk (MERK.JK), PT Phapros Tbk (PEHA.JK).
How has PT Indofarma Tbk's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 1.72 trillion IDR; FY2021, 2.90 trillion IDR; FY2022, 980.37 billion IDR; FY2023, 523.60 billion IDR; FY2024, 210.38 billion IDR.
Has PT Indofarma Tbk made a profit in recent years?
Net income by fiscal year: FY2020, 27.58 million IDR; FY2021, a loss of 37.58 billion IDR; FY2022, a loss of 457.62 billion IDR; FY2023, a loss of 720.99 billion IDR; FY2024, a loss of 334.49 billion IDR. It reported a net loss in 4 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “PT Indofarma Tbk (INAF.JK)”, data as of Sep 30, 2025, https://dataporium.tech/stocks/INAF.JK